PROSTAGLANDIN ANALOGUES

InPharma ◽  
1981 ◽  
Vol 314 (1) ◽  
pp. 6-7
Keyword(s):  
Prostaglandin Analogues

scholarly journals β-Ketophosphonates with Pentalenofuran Scaffolds Linked to the Ketone Group for the Synthesis of Prostaglandin Analogs

2021 ◽  
Vol 22 (13) ◽  
pp. 6787
Author(s):  
Constantin I. Tănase ◽  
Constantin Drăghici ◽  
Miron Teodor Căproiu ◽  
Anamaria Hanganu ◽  
Gheorghe Borodi ◽  
...  
Keyword(s):  
Lithium Salt ◽  
Methyl Esters ◽  
Secondary Compounds ◽  
Molecular Structures ◽  
Keto Group ◽  
High Yield ◽  
Oxidation Reactions ◽  
Prostaglandin Analogues ◽  
X Ray ◽  
Oxidation Of Alcohols

β-Ketophosphonates with pentalenofurane fragments linked to the keto group were synthesized. The bulky pentalenofurane skeleton is expected to introduce more hindrance in the prostaglandin analogues of type III, greater than that obtained with the bicyclo[3.3.0]oct(a)ene fragments of prostaglandin analogues I and II, to slow down (retard) the inactivation of the prostaglandin analogues by oxidation of 15α-OH to the 15-keto group via the 15-PGDH pathway. Their synthesis was performed by a sequence of three high yield reactions, starting from the pentalenofurane alcohols 2, oxidation of alcohols to acids 3, esterification of acids 3 to methyl esters 4 and reaction of the esters 4 with lithium salt of dimethyl methanephosphonate at low temperature. The secondary compounds 6b and 6c were formed in small amounts in the oxidation reactions of 2b and 2c, and the NMR spectroscopy showed that their structure is that of an ester of the acid with the starting alcohol. Their molecular structures were confirmed by single crystal X-ray determination method for 6c and XRPD powder method for 6b.

Stopping prostaglandin analogues in uneventful cataract surgery

2004 ◽  
Vol 30 (12) ◽  
pp. 2644-2645 ◽  
Author(s):  
Muhammad A. Ahad ◽  
Hamish D.R. McKee
Keyword(s):  
Cataract Surgery ◽  
Prostaglandin Analogues

Beneficial effects on the reproductive performance of sows of administering prostaglandin analogues after farrowing

2009 ◽  
Vol 164 (26) ◽  
pp. 807-809 ◽  
Author(s):  
J. V. Lopez ◽  
M. Ptaszynska ◽  
P. Gonzalez ◽  
M. Jimenez ◽  
M. R. T. M. Martens
Keyword(s):  
Reproductive Performance ◽  
Prostaglandin Analogues ◽  
Beneficial Effects

ChemInform Abstract: 7-Substituted Prostaglandin Analogues: A New Synthetic Approach.

ChemInform ◽  
1987 ◽  
Vol 18 (6) ◽  
Author(s):  
W. DANIKIEWICZ ◽  
T. JAWORSKI ◽  
S. KWIATKOWSKI
Keyword(s):  
Synthetic Approach ◽  
Prostaglandin Analogues

Prostaglandin analogues

1988 ◽  
Vol 2 (3) ◽  
pp. 621-628 ◽  
Author(s):  
Karsten Lauritsen ◽  
Jørgen Rask-Madsen
Keyword(s):  
Prostaglandin Analogues

Objective ocular surface tolerance in patients with glaucoma treated with topical preserved or unpreserved prostaglandin analogues

2018 ◽  
Vol 29 (6) ◽  
pp. 645-653 ◽  
Author(s):  
Ammar El Ameen ◽  
Guillaume Vandermeer ◽  
Raoul K Khanna ◽  
Pierre-Jean Pisella
Keyword(s):  
Intraocular Pressure ◽  
Prostaglandin Analogue ◽  
Ocular Toxicity ◽  
Prostaglandin Analogues ◽  
Conjunctival Hyperaemia ◽  
Ocular Symptoms ◽  
Tear Meniscus ◽  
Tear Meniscus Height ◽  
Preservative Free ◽  
Ocular Signs

Purpose: Preservatives in glaucoma medications have been associated with ocular toxicity. We compared ocular signs and symptoms in patients with open-angle glaucoma or ocular hypertension treated in monotherapy with preserved or preservative-free prostaglandin analogues. Methods: Observational cross-sectional clinical study in real life. 82 patients treated for at least 6 months with prostaglandin analogue were assessed for intraocular pressure, ocular symptoms and ocular signs including conjunctival hyperaemia, tear break-up time and tear meniscus height measured using objective and non-invasive methods (OCULUS Keratograph 5M). Patients presenting with symptoms of ocular toxicity with preserved prostaglandin analogues were switched to preservative-free latanoprost, and a second assessment was processed 6 months after. Results: At inclusion, 30 (36.6%) patients were treated with preservative-free latanoprost, 25 (30.5%) with preserved latanoprost, 16 (19.5%) with preserved travoprost and 11 (13.4%) with preserved bimatoprost. Patients treated with preservative-free latanoprost reported significantly less ocular symptoms upon instillation (mainly burning) and between instillations than patients treated with preserved prostaglandin analogues. The mean conjunctival hyperaemia (limbal + bulbar) was significantly lower with preservative-free latanoprost (2.08 ± 0.55) compared to preserved latanoprost (2.50 ± 0.7, p = 0.0085), preserved travoprost (2.67 ± 0.82, p = 0.0083) and preserved bimatoprost (2.68 ± 0.67, p = 0.0041). There were no relevant between-group differences in mean tear meniscus height and break-up time. Ocular symptoms and conjunctival hyperaemia improved when preserved prostaglandin analogues were switched to preservative-free latanoprost for 6 months while intraocular pressure reduction was maintained. Conclusion: Overall, this study suggests a better subjective and objective ocular tolerance when patients were treated with preservative-free latanoprost than with other preserved prostaglandin analogues monotherapy. Switching to preservative-free latanoprost maintained intraocular pressure at the same level as preservative prostaglandin analogue, but improved ocular surface tolerance.

Sign in / Sign up

Export Citation Format

Share Document